Endo Pharmaceuticals hit with subpoena over opioid products

Endo Pharmaceuticals (NSDQ:ENDP) was hit by a grand jury subpoena yesterday from the U.S. Attorney’s Office for the Southern District of Florida over its oxymorphone products. The subpoena requests an array of documents, including those derived from past or pending lawsuits, product safety and efficacy, overdoses, diversion, theft, abuse and misuse, withdrawal and addictiveness. Get the full story at our sister site, Drug Delivery Business News. The post Endo Pharmaceuticals hit with subpoena over opioid products appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Food & Drug Administration (FDA) Legal News Pain Management Pharmaceuticals Wall Street Beat Endo Pharmaceuticals Source Type: news